California Public Employees Retirement System decreased its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 55.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 391,759 shares of the company's stock after selling 483,267 shares during the quarter. California Public Employees Retirement System owned about 0.10% of Moderna worth $16,289,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allianz SE acquired a new position in shares of Moderna in the 4th quarter valued at $151,000. Aufman Associates Inc increased its holdings in shares of Moderna by 26.2% in the fourth quarter. Aufman Associates Inc now owns 11,066 shares of the company's stock valued at $460,000 after purchasing an additional 2,299 shares during the period. Allstate Corp purchased a new position in shares of Moderna in the fourth quarter worth about $396,000. DnB Asset Management AS lifted its holdings in shares of Moderna by 5.2% during the fourth quarter. DnB Asset Management AS now owns 57,755 shares of the company's stock worth $2,401,000 after purchasing an additional 2,865 shares during the period. Finally, Pictet Asset Management Holding SA boosted its position in Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after buying an additional 1,113,455 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
MRNA has been the subject of several research reports. Leerink Partners decreased their price objective on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research note on Thursday, January 16th. Royal Bank of Canada restated a "sector perform" rating and set a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Berenberg Bank increased their price target on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research report on Thursday, January 16th. Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. Finally, Argus lowered Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Moderna currently has an average rating of "Hold" and an average target price of $59.00.
Check Out Our Latest Research Report on MRNA
Moderna Stock Up 2.1 %
Shares of NASDAQ MRNA traded up $0.53 during midday trading on Monday, hitting $25.64. The stock had a trading volume of 13,240,479 shares, compared to its average volume of 7,069,830. The stock has a 50 day simple moving average of $33.55 and a 200-day simple moving average of $42.61. Moderna, Inc. has a 1 year low of $23.23 and a 1 year high of $170.47. The company has a market capitalization of $9.91 billion, a PE ratio of -2.76 and a beta of 2.23.
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
